Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Women's Health in the Lund Area (WHILA) study. Health problems and acute myocardial infarction in women - A 17-year follow-up study.

Maturitas·2018
Same author

Dementia and Alzheimer's disease risks in patients with autoimmune disorders.

Geriatrics & gerontology international·2018
Same author

The Genetic Epidemiology of Treated Major Depression in Sweden.

The American journal of psychiatry·2018
Same author

A Swedish Nationwide Adoption Study of the Heritability of Heart Failure.

JAMA cardiology·2018
Same author

Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.

Blood·2018
Same author

Familial risks in and between stone diseases: sialolithiasis, urolithiasis and cholelithiasis in the population of Sweden.

BMC nephrology·2018

Related Experiment Video

Updated: Jul 4, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Cancer risks in ulcerative colitis patients.

Kari Hemminki1, Xinjun Li, Jan Sundquist

  • 1Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany. k.hemminki@dkfz.de

International Journal of Cancer
|June 19, 2008
PubMed
Summary
This summary is machine-generated.

Ulcerative colitis patients face increased risks for various cancers, including novel sites like pancreatic and prostate cancers. Age at diagnosis influences cancer risk, with some risks potentially linked to heightened medical surveillance.

More Related Videos

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
08:51

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

Related Experiment Videos

Last Updated: Jul 4, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
08:51

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

Area of Science:

  • Gastroenterology
  • Oncology
  • Epidemiology

Background:

  • Ulcerative colitis (UC) patients have known risks for colorectal and liver cancers, and leukemia.
  • UC, an autoimmune condition, may be associated with a broader range of malignancies.

Purpose of the Study:

  • To investigate the comprehensive cancer risk in a large cohort of ulcerative colitis patients.
  • To identify novel cancer sites associated with UC and analyze age-dependent risk variations.

Main Methods:

  • A population-based cohort study using Swedish Hospital Discharge and Cancer Registries.
  • Follow-up of 27,606 UC patients (1964-2004) to identify 2,058 incident cancer cases.
  • Calculation of standardized incidence ratios (SIRs) comparing UC patients to the general population.

Main Results:

  • UC patients showed increased risks for 11 cancer sites, including small intestinal carcinoids, pancreatic, breast, prostate, nonthyroid endocrine tumors, non-Hodgkin lymphoma, and multiple myeloma.
  • Significant risks persisted for 6 sites after excluding cancers diagnosed in the year of UC hospitalization, with chronic myeloid leukemia also in excess.
  • Cancer risks varied by age at first UC hospitalization; colon, rectal, liver, and pancreatic cancer risks decreased with age, while endocrine tumor risks increased.

Conclusions:

  • Ulcerative colitis is associated with an expanded spectrum of subsequent cancers beyond established risks.
  • Novel associations, such as small intestinal carcinoids, prostate, and endocrine tumors, warrant further investigation, considering potential surveillance bias.
  • Age at UC diagnosis is a critical factor modifying cancer risk profiles in these patients.